One step closer to precision medicine for infectious diseases

Affiliations

¹ Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena 07740, Germany. Electronic address: mathias.pletz@med.uni-jena.de.
² Center for Sepsis Control and Care, Department of Anaesthesiology and Intensive Care Unit, Jena University Hospital, Jena 07740, Germany; Jena University Hospital, Jena 07740, Germany.
³ Department of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany; Institute of Microbiology, Friedrich Schiller University, Jena, Germany.

Comment

Mathias W Pletz et al. Lancet Infect Dis. 2019 Jun.

. 2019 Jun;19(6):564-565.

doi: 10.1016/S1473-3099(19)30070-2. Epub 2019 May 2.

¹ Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena 07740, Germany. Electronic address: mathias.pletz@med.uni-jena.de.
² Center for Sepsis Control and Care, Department of Anaesthesiology and Intensive Care Unit, Jena University Hospital, Jena 07740, Germany; Jena University Hospital, Jena 07740, Germany.
³ Department of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany; Institute of Microbiology, Friedrich Schiller University, Jena, Germany.

Erratum in

Correction to Lancet Infect Dis 2019; 19: 564-65.
[No authors listed] [No authors listed] Lancet Infect Dis. 2019 Aug;19(8):e259. doi: 10.1016/S1473-3099(19)30344-5. Epub 2019 Jun 19. Lancet Infect Dis. 2019. PMID: 31229426 No abstract available.

No abstract available

CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF, Colin G, Dequin PF, Dugernier T, Boulain T, Azeredo da Silveira S, Lajaunias F, Perez A, François B. Laterre PF, et al. Lancet Infect Dis. 2019 Jun;19(6):620-630. doi: 10.1016/S1473-3099(18)30805-3. Epub 2019 May 2. Lancet Infect Dis. 2019. PMID: 31056427